RBC Capital raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $58 from $55 and keeps an Outperform rating on the shares. The timelines for X-TOLE2 remain intact for early 2026, and the firm continues to see a high chance of success at 75% based on prior azetukalner phase 2b and OLE data, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals price target lowered to $44 from $48 at Wells Fargo
- Xenon Pharmaceuticals: Promising Drug Pipeline and Market Potential Drive Buy Rating
- Xenon Pharmaceuticals: Promising Pipeline and Upcoming Catalysts Drive Buy Rating
- Xenon Pharmaceuticals Reports Q3 2025 Financial Results
- Xenon Pharmaceuticals: Promising Pipeline and Strong Financial Position Justify Buy Rating